Skip to main content

CEL-SCI Corporation

corporate_fare Company Profile

CEL-SCI Corporation

CVM·NYSE·Life Sciences·CIK 0000725363

CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies with an emphasis on Multikine: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; and 2) L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review under CEL-SCI's future anticipated regulatory submission for approval. None of CEL-SCI's product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted. Immunotherapy is a large, high growth market. Immunotherapies use the patient's own immune system to fight disease. These "targeted therapies" are at the forefront of modern cancer research. A Bloomberg report from January 2023 asserted that the global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period.

CEL-SCI Corporation (NYSE:CVM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for CVM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Recent SEC coverage for CVM spans 8-K.

Recent high-impact activity:

  • CEL-SCI's Multikine Wins Saudi NADR Designation; FDA Clinical Hold Still in Place

Financial Snapshot

Fiscal year ended September 30, 2025
Net Income
-$25.41M
Diluted EPS
-$6.27
Op. Cash Flow
-$17.12M
Free Cash Flow
-$17.16M
Operating Income
-$24.81M
Cash & Equivalents
$10.95M
Debt / Equity
0.00×
Shares Outstanding
8.02M sh
Source: 10-K · filed 2025-12-23 · accession 0001654954-25-014303

Short Interest & Short Volume

5.96 days to cover

FINRA reported short interest of 705,801 shares in CVM as of the October 30, 2026 settlement, a 6.3% increase from the prior period — about 6.0 days to cover at its recent average daily volume. On November 20, 2026, 48.7% of CVM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)705,801 shares as of October 30, 2026
Change vs prior period▲ 6.3%
Days to cover5.96 at avg daily volume of 118,342
Daily short volume (FINRA facilities)48.7% of 519,249 shares on November 20, 2026
5-day average short volume56.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$1.23 +1.84% today
52-week range · as of 2026-11-20 $0.89 – $7.8
Market cap
$21.28M
Volume
880.3K (3.5× avg)
3-mo avg 251K
Live data · 2026-11-22 10:33 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CVM - Latest Insights

CVM
Nov 19, 2026, 9:55 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.42
Real-time Price: $1.23 info
Change: -$0.1877 (-13%) info
Market Cap: $21.283M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets